Although the frequency of emergent drug-resistant strains of HCV in patients who failed to respond to simeprevir plus pegylated interferon (PEG-IFN) and ribavirin (RBV) decreased after cessation of the treatment, it is not clear whether or not the NS3-D168 variants affect the outcome of NS5A and NS3 inhibitor combination therapy. In this study, we investigated the relationship between the effect of daclatasvir plus asunaprevir treatment and the frequencies of NS3-D168 variants.
Methods
HCV genotype-1b-infected human hepatocyte chimeric mice with various frequencies of NS3-D168 amino acid substitutions were treated with asunaprevir alone or in combination with daclatasvir for 4 weeks. Frequencies of NS3-D168 substitutions at baseline were analysed by ultra-deep sequencing. Some mice with NS3-D168 substitutions were treated with PEG-IFN or telaprevir for 4 weeks.
Results
Mice with high frequencies of NS3-D168 showed low susceptibility to asunaprevir treatment and failed to respond to daclatasvir plus asunaprevir therapy. In contrast, mice with a low frequency (less than approximately 14%) of NS3-D168 showed a similar susceptibility to wild-type HCV-infected mice and achieved viral eradication with daclatasvir plus asunaprevir therapy. Although treatment with either telaprevir or PEG-IFN resulted in reduction of serum HCV RNA levels, no significant decrease in the frequency of NS3-D168 substitutions was achieved.
Conclusions
Daclatasvir and asunaprevir treatment could eliminate NS3-D168 variant HCV if the frequency was low. It is necessary to confirm that the frequency of NS3-D168 variants has decreased sufficiently before adopting daclatasvir plus asunaprevir therapy in patients with simeprevir plus PEG-IFN/RBV treatment failure.
References
1.
NiederauC., LangeS., HeintgesT.Prognosis of chronic hepatitis C: results of a large, prospective cohort study.Hepatology1998; 28: 1687–1695.
2.
HayashiN., IzumiN., KumadaH.Simeprevir with peginterferon/ribavirin for treatment-naive hepatitis C genotype 1 patients in Japan: CONCERTO-1, a Phase III trial.J Hepatol2014; 61: 219–227.
3.
HayesC.N., KobayashiM., AkutaN.HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.Gut2011; 60: 261–267.
4.
HijikataM., MizushimaH., TanjiY.Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus.J Virol1993; 67: 4665–4675.
5.
ShimakamiT., WelschC., YamaneD.Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus.Gastroenterology2011; 140: 667–675.
6.
AkutaN., SuzukiF., SezakiH.Evolution of simeprevir-resistant variants over time by ultra-deep sequencing in HCV genotype 1b.J Med Virol2014; 86: 1314–1322.
7.
KumadaH., SuzukiY., IkedaK.Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.Hepatology2014; 59: 2083–2091.
8.
MercerD.F., SchillerD.E., ElliottJ.F.Hepatitis C virus replication in mice with chimeric human livers.Nat Med2001; 7: 927–933.
9.
KnetemanN.M., WeinerA.J., O'ConnellJ.Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application.Hepatology2006; 43: 1346–1353.
10.
HiragaN., ImamuraM., TsugeM.Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon.FEBS Lett2007; 581: 1983–1987.
11.
OharaE., HiragaN., ImamuraM.Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.J Hepatol2011; 54: 872–878.
12.
ShiN., HiragaN., ImamuraM.Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice.Gut2013; 62: 1055–1061.
13.
TatenoC., YoshizaneY., SaitoN.Near completely humanised liver in mice shows human-type metabolic responses to drugs.Am J Pathol2004; 165: 901–912.
14.
HiragaN., ImamuraM., AbeH.Rapid emergence of telaprevir resistant hepatitis C virus strain from wild-type clone in vivo.Hepatology2011; 54: 781–788.
15.
ElliottA.M., RadeckiJ., MoghisB., LiX., KammesheidtA.Rapid detection of the ACMG/ACOG-recommended 23 CFTR disease causing mutations using ion torrent semiconductor sequencing.J Biomol Tech2012; 23: 24–30.
16.
VogelU., SzczepanowskiR., ClausH., JünemannS., PriorK., HarmsenD.Ion torrent personal genome machine sequencing for genomic typing of Neisseria meningitidis for rapid determination of multiple layers of typing information.J Clin Microbiol2012; 50: 1889–1894.
17.
KatoT., MatsumuraT., HellerT.Production of infectious hepatitis C virus of various genotypes in cell cultures.J Virol2007; 81: 4405–4411.
18.
KarinoY., ToyotaJ., IkedaK.Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.J Hepatol2013; 58: 646–654.
19.
SatoM., MaekawaS., KomatsuN.Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus.J Virol2015; 89: 6105–6116.
20.
HalfonP., LocarniniS.Hepatitis C virus resistance to protease inhibitors.J Hepatol2011; 55: 192–206.
21.
YoshimiS., OchiH., MurakamiE.Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by Invader Assay.PLoS ONE2015; 10: e0130022.
